The U.S. Food and Drug Administration on Tuesday approvedPfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease. In June, the U.S. CDCnarrowedits recommendation for the use of respiratory...
The US Food and Drug Administration (FDA) has approved the first vaccine for respiratory syncytial virus (RSV) in the United States, the agency announced May 3. Arexvy, manufactured by GSK, is the world's first RSVvaccine for adults aged 60 years and older, the company said in an ...
The Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus down to age 50 years old, to those who are at higher risk of severe RSV, the companysaid Friday, making it the first shot greenlit for use in this age group to guard against RSV. Global va...
Older Americans this fall could get an RSV vaccine for the first time, after the Food and Drug Administration approved Wednesday a new shot from drugmaker GSK to guard against a virus that leads to thousands of hospitalizations and deaths in seniors. "Today's approval of the first RSV vaccine...
This is the first RSV vaccine for older adults to be approved anywhere in the world. Tony Wood, Chief Scientific Officer, GSK, said:“Today marks a turning point in our effort to reduce the significant burden of RSV. Arexvy is the first approved RSV vac...
The FDA has approved Moderna’s RSV vaccine for older adults. The Food and Drug Administration approved Moderna's vaccine for respiratory syncytial virus. The decision is a win for Moderna, which desperately needs another revenue source amid plunging demand for its...
FDA approves RSV vaccine The vaccine is approved for at-risk adults in their fifties, making it the first shot approved for the age group. June 8, 2024 Additional Live Streams Additional Live Streams Live ABC News Live Live Authorities investigate deadly New Year celebration terror attack in New...
Respiratory syncytial virus kills thousands of seniors every year. There currently is no approved vaccine for RSV. GSK's shot is administered as a single 120 microgram dose. Both companies have asked the FDA to approve their RSV shot for adults ages 60 and older. The agency ...
GSK plc today announced that the FDA has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.
The first vaccine for respiratory syncytial virus (RSV) has been approved by the U.S. Food and Drug Administration for use in seniors aged 60 and older.